Sidewinder Therapeutics, a San Diego, CA-based biopharmaceutical company developing ADCs for the treatment of cancer, has raised $137 million in a Series B funding round led by Frazier Life Sciences and Novartis Venture Fund.
The round also saw participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management and Alexandria Venture Investments.
Along with the funding, Daniel Estes, Michal Silverberg, Josh Richardson, and John Hamer joined the company’s Board of Directors. The raise brought the total amount to $162M.
The company plans to use the funds to move its main program into clinical development by 2027.
Sidewinder focuses on developing special cancer treatments called bispecific ADCs, which are designed to target specific receptor pairs found in certain solid tumors. Its pipeline uses carefully engineered antibodies, built from its own discoveries, to target these tumor-specific receptor combinations. This precise approach helps the treatment better enter cancer cells while avoiding healthy cells, improving how drugs are delivered.
Read More:PeakMetrics Raises $6M in Series A Funding
The company is working on cancers that have limited treatment options but affect many people, including lung and head and neck cancers, as well as gastrointestinal cancers like colorectal cancer. Sidewinder plans to move its lead program into clinical development by 2027.
“We’re happy to have the support of this strong group of investors who believe in our mission to develop next-generation cancer treatments,” said Eric Murphy, Co-Founder and CEO of Sidewinder Therapeutics. “New technology is creating big opportunities in the ADC field, and Sidewinder aims to lead this progress and bring better treatment options to cancer patients.”
“Built on strong science and a unique approach, Sidewinder’s bispecific ADC pipeline could help solve key challenges in safety and effectiveness for these treatments,” said Daniel Estes of Frazier Life Sciences. “We believe Sidewinder Therapeutics can make major progress in this field and improve how cancer is treated.”
About Sidewinder Therapeutics
Founded in 2023, by Eric Murphy, Sidewinder Therapeutics is developing next-generation cancer treatments called bispecific ADCs, designed to target tumors better and improve drug delivery into cancer cells. The company has partnered with Lonza to use Synaffix’s specialized technology across several programs. Backed by OrbiMed Sidewinder is based in San Diego and has raised $162 million from leading investors.
Read More:CertifID Raises $47.5M in Series C Funding
